Trial · NCT02324803
Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
NCT02324803, Phase 2, Unknown, Southern China Urology Cancer Consortium
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients. Trials, record NCT02324803. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02324803
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients
- NCT number
- NCT02324803
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 86 participants, estimated
- Lead sponsor
- Southern China Urology Cancer Consortium
- Conditions
- Self Efficacy, Adverse Drug Event, Carcinoma, Renal Cell
- Interventions
- pazopanib
- First posted
- 2014-12-24
- Last updated
- 2014-12-24
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | progression-free survival (PFS) | pazopanib treatment until earliest date of disease progression or death, assessed up to 30 months after the last patient has been enrolled | |
| Secondary | Overall survival of patients treated with second-line pazopanib therapy | Initiation of pazopanib dose until death, assessed up to 30 months after the last patient has been enrolled | |
| Secondary | Objective Response Rate to pazopanib therapy | Initiation of pazopanib treatment until time of confirmed best response, assessed up to 30 months after the last patient has been enrolled | |
| Secondary | Number of grade 3 or 4 adverse events attributable to pazopanib | Time of first dose of pazopanib to approximately one month after discontinuation of pazopanib |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02324803
GET https://conductscience.org/api/trials/v1/NCT02324803/registered